Timo Minssen (Former)
61 – 70 of 103
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
Will clinical trial data disclosure reduce incentives to develop new uses of drugs?
- Contribution to journal › Article
-
Mark
Life after Myriad: the uncertain future of patenting biomedical innovation and personalised medicine in an international context
- Contribution to journal › Article
-
Mark
Enforcing patents in the era of 3D printing
- Contribution to journal › Article
-
Mark
IPRs in Biobanking: Risks and Opportunities for Translational Research
- Contribution to journal › Article
-
Mark
Standardization, IPRs and open innovation in synthetic biology
(2015) p.34-66
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
A “ray of hope” for European stem cell patents or “out of the smog into the fog”?: The CJEU decision in C-364/13 and how it compares to recent US developments.(under review)
(2015) In Biotechnology Law Report
- Contribution to journal › Article
-
Mark
Synthetic biology and intellectual property rights: Six recommendations
- Contribution to journal › Article
- 2014
-
Mark
Book Review: Drexl, J., Lee, N. (2013). Pharmaceutical Innovation, Competition and Patent Law : A Trilateral Perspective. Edward Elgar Publishing
- Contribution to journal › Review (Book/Film/Exhibition/etc.)
-
Mark
The ”opt out” and “opt in” provisions in the Unified Patent Court Agreement – Impact and strategies for European patent portfolios
- Contribution to journal › Article
-
Mark
Legal aspects of biobanking as key issues for personalized medicine and translational exploitation
- Contribution to journal › Article
